Market icon
Series: fda approvalsciencebusinesstechdrugfdamedicine

FDA approves Elevar Therapeutics' Rivoceranib + camrelizumab?

Resolved: No
Started 7/1/2026
Resolved 7/11/2026
View on Polymarket

Total Volume

$1.63K

Total betting volume on this market

Total Profits

$71.65

Net profit earned by winners

Total Fees

$2.16

Total trading fees generated

Total Traders

26

Unique addresses participated

Top 20 Winners (Total 3)

PnL+$53.14
ROI+3.4%
Volume18 orders · fee $1.81
Bought 1,600.40 No shares at avg $0.97 costing $1,545.06
Bought 1.39 Yes shares at $0.28 costing $0.39
PnL+$18.13
ROI+1007.5%
Volume1 order · fee $0.07
Bought 20.00 No shares at $0.09 costing $1.80
PnL+$0.38
ROI+37.8%
Volume1 order · fee $0.01
Bought 1.39 No shares at $0.72 costing $1.00